Cholangiocarcinomas Completed Phase 2 Trials for Capecitabine (DB01101)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00779454Combined Biological Treatment and Chemotherapy for Patients With Inoperable CholangiocarcinomaTreatment
NCT01206049Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS MutationsTreatment
NCT01007552A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile DuctsTreatment